Emmaus Life SciencesEMMA +0.01% Return-on-Tangible-Asset is -66.48% as of Mar. 2026. The stock has 6 warning signs investors should review. Among 1,412 Biotechnology companies, Emmaus Life Sciences ranks worse than 52.76% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Emmaus Life Sciences's annualizedNet Income for the quarter that ended in Mar. 2026 was $-13.34 Mil. Emmaus Life Sciences's average total tangible assets for the quarter that ended in Mar. 2026 was $20.07 Mil. Therefore, Emmaus Life Sciences's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was -66.48%.
The historical rank and industry rank for Emmaus Life Sciences's Return-on-Tangible-Asset or its related term are showing as below:
EMMA'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -1213.69 Med: -30.35 Max: 2.28
Current: -39.81
During the past 13 years, Emmaus Life Sciences's highest Return-on-Tangible-Asset was 2.28%. The lowest was -1213.69%. And the median was -30.35%.
EMMA's Return-on-Tangible-Asset is ranked worse than 52.76% of 1412
companies
in the Biotechnology industry
Industry Median: -35.66
vs EMMA: -39.81
Emmaus Life Sciences (OTCPK:EMMA) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Emmaus Life Sciences Return-on-Tangible-Asset Related Terms
Emmaus Life Sciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Emmaus Life Sciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Emmaus Life Sciences Return-on-Tangible-Asset Chart
EMMA vs PTIX, BZYR, RMTG: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Emmaus Life Sciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Emmaus Life Sciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Emmaus Life Sciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of -66.48% mean?
Emmaus Life Sciences (EMMA) has a Return-on-Tangible-Asset of -66.48% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #745 out of 1412 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Emmaus Life Sciences' Return-on-Tangible-Asset too high?
Emmaus Life Sciences' current Return-on-Tangible-Asset is -66.48%. Based on the distribution chart, Emmaus Life Sciences ranks #745 out of 1412 companies in the Biotechnology industry, which is below the industry midpoint.
How does Emmaus Life Sciences' Return-on-Tangible-Asset compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #745 out of 1412 companies for Return-on-Tangible-Asset. This places Emmaus Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Return-on-Tangible-Asset is -66.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14.2% above its estimated fair value. The current Return-on-Tangible-Asset is -66.48%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Return-on-Tangible-Asset is -66.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EMMA has been successfully added to your 